VIDEO: ‘Unique’ protocol expands transplant pool to include HCV-infected donors
Click Here to Manage Email Alerts
BOSTON — In this video, Norah Terrault, MD, MPH, FAASLD, spoke with Healio about a presentation from The Liver Meeting on “The Toronto Protocol,” an ultra-short course of glecaprevir/pibrentasvir with ezetimibe.
According to Terrault, the 7-day protocol is designed to prevent chronic hepatitis C virus infection when transplanting solid organs from HCV-infected donors to noninfected recipients.
“That combination is successful in preventing infection in these solid organ transplants of kidney, heart and liver,” Terrault, professor of medicine, chief of gastroenterology and liver diseases, and Neil Kaplowitz Endowed Chair in Liver Diseases Research at the University of Southern California Keck School of Medicine, told Healio. “That is also a very unique, important and cost-effective approach to expanding the donor pool and potentially having more patients receive organs rather than having these organs not be used.”